TC BioPharm Holdings Plc (TCBP)

[resx18]

$TCBP #TEAM

[Mrogers23]

$TCBP, question who is we?

[resx18]

Nice another update should be soon imo $TCBP

[rbb]

looking good,,, added a few more today... $TCBP

[resx18]

Agreed $TCBP

[resx18]

$TCBP will run all week

[resx18]

$TCBP premarket news on a Monday got #shorts by the ballz .. #MOASS #GoodCall

[resx18]

$1 is no prob $TCBP

[resx18]

1-yr high is $22.

Yes indeed $TCBP

[resx18]

We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development.

[resx18]

https://t.me/marketwirenews/64754

[resx18]

$TCBP doing great work

[resx18]

The FDA will review the application and determine the acceptability of the data before TC BioPharm begins its first clinical trial for TCB-008 It is possible that the FDA will require additional information.

[resx18]

I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."

[resx18]

"The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team.

[resx18]

"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm.

[resx18]

The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.

[resx18]

#CancerSucks $TCBP has the answers

[resx18]

Livin and lovin the new followers $TCBP #WeHaveThePower

[resx18]

https://stocktwits.com/resx18/message/548683881

[resx18]

Ground floor BioPharm play @ .40

[resx18]

Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia

[resx18]

"TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm.

[resx18]

"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm.

[resx18]

The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.

[resx18]

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008, an allogeneic unmodified gamma delta t-cell, is the Company's lead product and is currently in Phase 2b trials in the U.K. for the treatment of AML.).

[resx18]

Filing is supported by strong clinical data and IND enabling pre-clinical data associated withTCB-008 in treatment of Acute Myeloid Leukemia

[resx18]

OmnImmune® an allogeneic unmodified cell therapy consisting of activated and expanded gamma delta T cells. The trial, for treatment of patients suffering from relapse/refractory Acute Myeloid Leukemia (AML). The therapeutic comprises GDT cells sourced from healthy donors, expanded and activated in large numbers before being purified and formulated for infusion into patients. OmnImmune® is a frozen and thawed product, now "banked" from donor derived cells.

[resx18]

@Mrogers23 @Trooperstocks $TCBP is just getting started!

[resx18]

$TCBP looking good into tomorrow!

[resx18]

$TCBP website > https://tcbiopharm.com/

[resx18]

TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease.

[resx18]

Lots of new followers! Great to see! $TCBP Strong!!

[resx18]

Great start @Mrogers23 welcome to $TCBP

[Mrogers23]

Nice to see 2x a G vol early

[resx18]

The FDA will review the application and determine the acceptability of the data before TC BioPharm begins its first clinical trial for TCB-008 It is possible that the FDA will require additional information.

[resx18]

Bryan Kobel (great CEO) of $TCBP said . "The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team. I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."

[resx18]

$TCBP loaded last week

[resx18]

Welcome onboard jedijazz! $TCBP

[resx18]

"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm. "The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team. I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."

[Trooperstocks]

Great alert @Ryguy008

[resx18]

Reminds me of Dice .. $TCBP

[resx18]

Awesome 500k volume on news $TCBP

[resx18]

.45's up +20% $TCBP

[Ryguy008]

Big boys entered the building last night and today. Last week slow

$TCBP

[resx18]

$TCBP premarket news on a Monday got #shorts by the ballz .. #MOASS

[resx18]

https://stocktwits.com/resx18/message/548683881

[resx18]

EDINBURGH, Scotland , Oct. 23, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008, an allogeneic unmodified gamma delta t-cell, is the Company's lead product and is currently in Phase 2b trials in the U.K. for the treatment of AML.).

TC BioPharm (PRNewsfoto/TC BioPharm)

The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.

"Filing of the IND for TCB-008 is the next step in the clinical development of TCB-008 and aligns with our strategic refocus announced in Q2 of this year to target our clinical strategy to US trials in the future." said Bryan Kobel, Chief Executive Officer of TC BioPharm. "The IND application leverages supporting clinical study data from ongoing studies in patients with Acute Myeloid Leukemia and is also a reflection of substantial pre-clinical IND enabling work done over the course of the last 6 months by the TCB team. I would like to thank our entire team, who worked tirelessly to complete the Company's first ever US FDA trial filing. We look forward to working closely with the FDA to garner acceptance of our IND over the coming 30 days and advancing our lead candidate through clinical phases of development."

The FDA will review the application and determine the acceptability of the data before TC BioPharm begins its first clinical trial for TCB-008 It is possible that the FDA will require additional information.

[resx18]

Did you see the update? $TCBP

[resx18]

https://x.com/resx18/status/1716426111813312514?s=20